Skip to playerSkip to main contentSkip to footer
  • 6/15/2012
Kirkland's' Daniel Wolf tells The Deal Pipeline about his unique experience in advising Bristol-Myers Squibb in its $2.5 billion acquisition of Inhibitex.

Recommended